Rights and Permissions
King RL, Nowakowski GS, Witzig TE, Scott DW, Little RF, Hong F, Gascoyne RD, Kahl BS, Macon WR. Rapid, real time pathology review for ECOG/ACRIN 1412: a novel and successful paradigm for future lymphoma clinical trials in the precision medicine era. Blood Cancer J. 2018 Feb 28;8(3):27. doi: 10.1038/s41408-018-0064-9.
Copyright The Author(s) 2018
OpenThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction
in any mediumor format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
King, Rebecca L.; Nowakowski, Grzegorz S.; Witzig, Thomas E.; Scott, David W.; Little, Richard F.; Hong, Fangxin; Gascoyne, Randy D.; Kahl, Brad S.; and Macon, William R., ,"Rapid, real time pathology review for ECOG/ACRIN 1412: A novel and successful paradigm for future lymphoma clinical trials in the precision medicine era." Blood Cancer Journalvolume.8,. . (2018).